Examine This Report on LDN-27219 potential therapeutic applications
A single specifically interesting compound is LDN-27219. While most tTG inhibitors are meant to bind to your protein crosslinking active site, LDN-27219 in its place binds towards the nucleotide binding pocket of the enzyme when it truly is in its shut-state conformation, and stabilizes that conformation to circumvent crosslinking activity.78 Schne